Prodigiosins as anti cancer agents: Living upto their name

Current Pharmaceutical Design

Volumn 15, Issue 7, 2009, Pages 732-741

  Pandey, Ruchi ^a   Chander, R ^a   Sainis, K B ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

Anti cancer; Apoptosis; Prodigiosin; Signal transduction

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; CASPASE 9; CISPLATIN; CYCLOPRODIGIOSIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PRODIGIOSIN; PROTEIN BCL 2; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DNA DAMAGE; DRUG DNA BINDING; DRUG EFFICACY; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG TRANSPORT; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; HUMAN; IC 50; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARGET CELL DESTRUCTION; ANIMAL; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; GRAM-NEGATIVE BACTERIA; HUMANS; NEOPLASMS; PRODIGIOSIN; TRANSCRIPTION FACTORS;

EID: 64549162769     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582192     Document Type: Review

References (82)

1. Bennett JW, Bentley R. Seeing red: The story of prodigiosin. Adv Appl Microbiol 2000; 47: 1-32.
2. Frustener A. Chemistry and biology of roseophilin and the prodigiosin alkaloids: A survey of the last 2500 years. Angew Chem Int Ed 2003; 42: 3582-603.
3. Williamson NR, Fineran PC, Gristwood T, Chawrai SR, Leepaer FJ, Salmond GP. Anticancer and immunosuppressive properties of bacterial prodiginines. Future Microbiol 2007; 2: 605-18.
4. Gerber NN. Prodigiosin-like pigments. CRC Crit Rev Microbiol 1975; 3: 469-85.
5. Williams RP, Quadri SM. In: Von Graevenitz A, Rubin SJ, Eds. The Pigments of Serratia in the Genus Serratia. Boca Raton, CRC Press Inc. 1980; 31-75.
6. Variyar PS, Chander R, Venkatachalam SR, Bongirwar DR. A new red pigment from an alkalophilic Micrococcus species. Indian J Chem 2002; 41: 232-3.
7. Deorukhkar AA, Chander R, Ghosh SB, Sainis KB. Identification of a red-pigmented bacterium producing a potent anti-tumor N-alkylated prodigiosin as Serratia marcescens. Res Microbiol 2007; 158: 399-404.
8. Pandey R, Chander R, Sainis KB. Prodigiosins: A novel family of immunosuppressants with anti-cancer activity. Indian J Biochem Biophys 2007; 44: 295-92.
9. Stepkowski SM, Erwin-Cohen RA, Behbod F, Wang ME, Qu X, Tejpal N, et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002; 99: 680-9.
10. Wang M, Kirken R, Behbod F, Erwin-Cohen R, Stepkowski SM, Kahan BD. Inhibition of Jak3 tyrosine kinase by PNU156804 blocks rat heart allograft rejection. Transplant Proc 2001; 33: 201.
11. Han SB, Park SH, Jeon YJ, Kim YK, Kim HM, Yang KH. Prodigiosin blocks T cell activation by inhibiting interleukin-2Ralpha expression and delays progression of autoimmune diabetes and collagen-induced arthritis. J Pharmacol Exp Ther 2001; 299: 415-25.
12. Podder H, Kahan BD. Janus kinase 3: A novel target for selective transplant immunosupression. Expert Opin Ther Targets 2004; 8: 613-29
13. Cetkovic-Cvrlje M, Uckun FM. Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases. Arch Immunol Ther Exp 2004; 52: 69-82.
14. Manderville RA. Synthesis, proton-affinity and anti-cancer properties of the prodigiosin-group natural products. Curr Med Chem - Anti-Cancer Agents 2001; 1: 195-218.
15. Soto-Cerrato V, Francesc V, Lambert JR, Perez-Tomas R. The anti-cancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway. Biochem Pharmacol 2007; 74: 1340-9.
16. Lai K S, Jin Y, Graham DK, Witthuhn BA, Ihle JN, Liu ET. A kinase-deficient splice variant of the human Jak3 is expressed in hematopoietic and epithelial cancer cells. J Biol Chem 1995; 270: 25028-36.
17. Montaner B, Perez-Tomas R. The prodigiosins: A new family of anticancer drugs. Curr Cancer Drug Targets 2003; 3: 57-65.
18. Perez-Tomas R, Montaner B, Llagostera E, Soto-Cerrato V. The prodigiosins, proapoptotic drugs with anticancer properties. Biochem Pharmacol 2003; 66: 1447-52.
19. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage. Curr Med Chem 2008; 15: 422-32.
20. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006; 33: 407-20.
21. +/ Cl-symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Hepatology 1999; 30: 894-902.
22. Montaner B, Navarro S, Pique M, Vilaseca M, Martinell M, Giralt E, et al. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. Br J Pharmacol 2000; 131: 585-93.
23. Francisco R, Perez-Tomas R, Giménez-Bonafe P, Soto Cerrato V, Giménez-Xavier P, Ambrosio S. Mechanisms of prodigiosin cytotoxicity in human neuroblastoma cell lines. Eur J Pharmacol 2007; 572: 111-19.
24. -symporter, induces apoptosis in human breast cancer cell lines. J Cancer Res Clin Oncol 2002; 126: 191-7.
25. Yamamoto D, Uemura Y, Tanaka K, Nakai K, Yamamoto C, Takemoto H, et al. Cycloprodigiosin hydrochloride H+/Cl-symporter induces apoptosis and differentiation in HL-60 cells. Int J Cancer 2002; 88: 121-8.
26. -symporter, induces apoptosis in human colon cancer cell lines in vitro. Oncol Rep 2001; 8: 821-4.
27. Diaz-Ruiz C, Montaner B, Perez-Tomas R. Prodigiosin induces cell death and morphological changes indicative of apoptosis in gastric cancer cell line HGT-1. Histol Histopathol 2001; 16: 415-21.
28. Montaner B, Perez-Tomas R. Prodigiosin-induced apoptosis in human colon cancer cells. Life Sci 2001; 68: 2025-36.
29. Soto-Cerrato V, Llagostera E, Montaner B, Scheffer GL, Perez-Tomas R. Mitochondria mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. Biochem Pharmacol 2004; 68: 1345-52.
30. Nakashima T, Tamura T, Kurachi M, Yamaguchi K, Oda T. Apoptosis-mediated cytotoxicity of prodigiosin-like red pigment produced by gamma-Proteobacterium and its multiple bioactivities. Biol Pharm Bull 2005; 28: 2289-95.
31. Liu R, Cui CB, Duan L, Gu QQ, Zhu WM. Potent in vitro anticancer activity of metacycloprodigiosin and undecylprodigiosin from a sponge-derived actinomycete Saccharopolyspora sp. nov. Arch Pharm Res 2005; 28: 1341-1344.
32. Ho TF, Ma CJ, Lu CH, Tsai YT, Wei YH, Chang JS, et al. Undecylprodigiosin selectively induces apoptosis in human breast carcinoma cells independent of p53. Toxicol Appl Pharmacol 2007; 225: 318-28.
33. Deorukhkar AA, Chander R, Pandey R, Sainis KB. A novel N-alkylated prodigiosin analogue induced cell death in tumor cells through apoptosis or necrosis depending upon the cell type. Cancer Chemother Pharmacol 2008; 61: 355-63.
34. Subramanian M, Chander R, Chattopadhyay S. A novel naturally occurring tripyrrole with potential nuclease and anti-tumor properties. Bioorg Med Chem 2006; 14: 2480-6.
35. Baldino CM, Parr J, Wilson CJ, Ng SC, Yohannes D, Wasserman HH. Indoloprodigiosins from the C-10 bipyrrolic precursor: New antiproliferative prodigiosin analogs. Bioorg Med Chem Lett 2006; 16: 701-4.
36. Campas C, Dalmau M, Montaner B, Barragan M, Bellosillo B, Colomer D, et al. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Leukemia 2003; 17: 746-50.
37. Kawauchi K, Tobiume K, Iwashita K, Inagaki H, Morikawa T, Shibukawa Y, et al. Cycloprodigiosin hydrochloride activates the Ras-PI3K-Akt pathway and suppresses the protein synthesis inhibition induced apoptosis in PC12 cells. Biosci Biotechnol Biochem 2008; 72: 80064-7
38. Llagostera E, Soto-Cerrato V, Joshi R, Montaner B, Gimenez-Bonafe P, Perez-Tomas R. High cytotoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activation. Anticancer Drugs 2005; 16: 393-9.
39. Sherr CJ. Principles of tumor suppression. Cell 2004;116: 235-46.
40. Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. Cell Death Differ 2006; 13: 994-1002.
41. Zhang J, Shen Y, Liu J, Wei D. Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem Pharmacol 2005; 69: 407-14.
42. Kataoka T, Muroi M, Ohkuma S, Waritani T, Magae J, Takatsuki A, et al. Prodigiosin 25-C uncouples vacuolar type H(+)-ATPase, inhibits vacuolar acidification and affects glycoprotein processing. FEBS Lett 1995; 359: 53-9.
43. Konno H, Matsuya H, Okamoto M, Sato T, Tanaka Y, Yokoyama K, et al. Prodigiosins uncouple mitochondrial and bacterial F-ATPases: evidence for their H+/Cl-symport activity. J Biochem 1998; 124: 547-56.
44. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98: 2603-14.
45. Cowling V, Downward J. Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: Absolute requirement for removal of caspase-6 prodomain. Cell Death Differ 2002; 9: 1046-56.
46. Fulda S, Debatin KM. Exploiting death receptor signaling pathways for tumor therapy. Biochim Biophys Acta 2004; 1705: 27-41.
47. Llagostera E, Soto-Cerrato V, Montaner B, Perez-Tomas R. Prodigiosin induces apoptosis by acting on mitochondria in human lung cancer cells. Ann N Y Acad Sci 2003; 1010: 178-81.
48. Montaner B, Perez-Tomas R. Prodigiosin induces caspase-9 and caspase-8 activation and cytochrome C release in Jurkat T cells. Ann N Y Acad Sci 2002; 973: 246-9.
49. Soto-Cerrato V, Francesc V, Lambert JR, Kelly JA, Perez-Tomas R. Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3β activity in human breast cancer cells. Mol Cancer Ther 2007; 6: 362-9.
50. Breckenridge D, Xue D. Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases. Curr Opin Cell Biol 2004; 16: 647-52.
51. Igney FH, Krammer PH. Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-288.
52. Degterev A, Boyce M, Yuan J. A decade of caspases, death and anti-death: tumour resistance to apoptosis. Oncogene 2003; 22: 8543-67.
53. Leist M, Jaattela. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001; 2: 589-98.
54. Shrode LD, Tapper H, Grinstein S. Role of intracellular pH in proliferation, transformation, and apoptosis. J Bioenerg Biomembr 1997; 29: 393-9.
55. Ohkuma S, Sato T, Okamoto M, Matsuya H, Arai K, Kataoka T, et al. Prodigiosins uncouple lysosomal vacuolar-type ATPase through promotion of H+/Cl-symport. Biochem J 1998; 334: 731-41.
56. Seganish JL, Davis JT. Prodigiosin is a chloride carrier that can function as an anion exchanger. Chem Commun (Camb) 2005; 14:5781-3.
57. Castillo-Avila W, Abal M, Robine S, Perez-Tomas R. Non-apoptotic concentrations of prodigiosin (H+/Cl-symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells. Life Sci 2005; 78: 121-7.
58. Kawauchi K, Tobiume K, Kaneko S, Kaneshiro K, Okamoto S, Ueda E, et al. Suppression of AP-1 activity by cycloprodigiosin hydrochloride. Biol Pharm Bull 2007; 30: 1792-5.
59. Perez-Tomas R, Montaner B. Effects of the proapoptotic drug prodigiosin on cell cycle-related proteins in Jurkat T cells. Histol Histopathol 2003; 18: 379-85.
60. Songia S, Mortellaro A, Taverna S, Fornasiero C, Scheiber EA, Erba E, et al. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: Retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets. J Immunol 1997; 158: 3987-95.
61. Mortellaro A, Songia S, Gnocchi P, Ferrari M, Fornasiero C, D'Alessio R, et al. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kappa B and AP-1 activation. J Immunol 1999; 162: 7102-9.
62. Pandey R, Chander R, Sainis KB. Role of interleukin-2 regulated proteins in immunosuppression by the N-alkylated prodigiosin analogue. Int Immunopharmacol 2007; 7: 1695-703.
63. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006; 12: 440-50.
64. Melvin MS, Ferguson DC, Lindquist N, Manderville RA. DNA binding by 4-methoxypyrrolic natural products. Preference for intercalation at AT sites by tambjamine e and prodigiosin. J Org Chem 1999; 64: 6861-9.
65. Montaner B, Castillo-Avila W, Martinell M, Ollinger R, Aymami J, Giralt E, et al. DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin. Toxicol Sci 2005; 85: 870-9.
66. Melvin MS, Tomlinson JT, Saluta GR, Kucera GL, Lindquist N, Manderville RA. Double-strand DNA cleavage by copper-prodigiosin. J Am Chem Soc 2000; 122: 6333-4.
67. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005; 67: 356-4.
68. Ramoneda BM, Perez-Tomas R. Activation of protein kinase C for protection of cells against apoptosis induced by the immunosuppressor prodigiosin. Biochem Pharmacol 2002; 63: 463-9.
69. Kawauchi K, Shibutani K, Yagisawa H, Kamata H, Nakatsuji S, Anzai H, et al. A possible immunosuppressant, cycloprodigiosin hydrochloride, obtained from Pseudoalteromonas denitrificans. Biochem Biophys Res Commun 1997; 237: 543-7.
70. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-6.
71. Montaner B, Perez-Tomas R. The cytotoxic prodigiosin induces phosphorylation of p38-MAPK but not of SAPK/JNK. Toxicol Lett 2002; 129: 93-8.
72. Olivier S, Robe P, Bours V. Can NF-kappaB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol 2006; 72: 1054-68.
73. Huh JE, Yim JH, Lee HK, Moon EY, Rhee DK, Pyo S. Prodigiosin isolated from Hahella chejuensis suppresses lipopolysaccharide-induced NO production by inhibiting p38 MAPK, JNK and NF-κB activation in murine peritoneal macrophages. Int Immunopharmacol 2007; 7: 1825-33.
74. Kamata K, Okamoto S, Oka S, Kamata H, Yagisawa H, Hirata H. Cycloprodigiosin hydrocloride suppresses tumor necrosis factor (TNF) -α induced transcriptional activation by NF-κB. FEBS Lett 2000; 507: 74-80.
75. Carter AB, Knudtson KL, Monick MM, Hunninghake GW. The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP). J Biol Chem 1999; 274: 30858-63.
76. Nakashima T, Kurachi M, Kato Y, Yamaguchi K, Oda T. Characterization of bacterium isolated from the sediment at coastal area of Omura Bay in Japan and several biological activities of pigment produced by this isolate. Microbiol Immunol 2005; 49: 407-15.
77. Mourskaia AA, Northey JJ, Siegel PM. Targeting aberrant TGF-beta signaling in pre-clinical models of cancer. Anticancer Agents Med Chem 2007; 7: 504-14.
78. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001; 12: 375-91.
79. Yang Q, Guan KL. Expanding mTOR signaling. Cell Res 2007; 17: 666-81
80. Ayala A, Perl M, Venet F, Lomas-Neira J, Swan R, Chung CS. Apoptosis in sepsis: Mechanisms, clinical impact and potential therapeutic targets. Curr Pharm Des 2008; 14(19): 1853-9.
81. Bergmann-Leitner E. Anti-cancer drugs. Curr Pharm Des 2008; 14(11): 1048.
82. van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des 2008; 14(21): 2061-74.